News | Cath Lab | May 26, 2022

Abbott Medical Recalls Dragonfly OpStar Imaging Catheter for Potential Loose Catheter Marker Band

The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has identified this as a Class I recall, the most serious type of recall.

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death.

The Dragonfly OpStar imaging catheter with optical coherence tomography (OCT) imaging system is designed to provide imaging of blood vessels that carry blood and oxygen to the heart (coronary arteries) in people who are candidates for catheter-based, minimally invasive, interventional procedures to address coronary artery disease.

Reason for Recall

Abbott is recalling certain lots of the Dragonfly OpStar imaging catheter because the marker band farthest from the catheter tip (proximal marker) may become loose and, in two instances, has been observed to separate from the catheter while being used on a person.

A loose marker band that has separated from the device may remain in the body after the catheter is removed, potentially leading to vascular injuries, including but not limited to embolism (blockage of the vessel), thrombosis (blood clot), dissection (tear), ischemia (inadequate blood supply to the heart), infarction (heart attack), infection, or death.

There have been 5 incidents and 1 injury related to this device issue. No deaths have been associated with the use of this device due to this issue.

Who May be Affected

  • Health care personnel who use the Dragonfly OpStar Imaging Catheter for OCT imaging of the coronary arteries.
  • People who will have catheter-based OCT imaging of the coronary arteries using the Dragonfly OpStar Imaging Catheter. This issue does not impact people who have already had this procedure.

Recalled Product

  • Product Name: Dragonfly OpStar Imaging Catheter

  • Product Lot Numbers: See recall database entry

  • Devices Recalled in the U.S.: 4,800

  • Date Initiated by Firm: April 11, 2022

What to Do

On April 11, 2022, Abbott issued an Urgent Medical Device Recall letter to all customers who received affected devices. The following instructions were included:

  • Immediately stop using devices from affected lots
  • Review inventory and complete the Effectiveness Check Form Included with the Urgent Medical Device recall letter.
  • Return all unused affected devices to Abbott.
  • Share this information with all relevant personnel.
  • Notify anyone who may have received these affected products through additional distribution or transfer.
  • Report any product performance issues or adverse events to Abbott.

Contact Information

Customers with questions or concerns about this recall should contact their local Abbott representative or call the customer service department at 800-227-9902.

Related Dragonfly OpStar Imaging Catheter information:

FDA Clears Abbott OCT Imaging Enhanced With Artificial Intelligence

Abbott’s New Artificial Intelligence OCT Coronary Imaging Platform Launches in Europe


Related Content

Feature | Cardiovascular Business | By Melinda Taschetta-Millane

It is a new year with lots of new content! Here is a look at the most-read content during the month of January on ...

Home February 01, 2024
Home
Feature | Cardiovascular Business

Did you know that Diagnostic and Interventional Cardiology (DAIC) maintains more than 40 comparison charts of product ...

Home January 29, 2024
Home
News | Cardiovascular Business

January 24, 2024 — Medtronic announced the recent appointment of Simona Zannetti, MD, as the General Manager of its ...

Home January 24, 2024
Home
News | Cardiovascular Business

January 22, 2024 — The American College of Cardiology is again urging members of Congress to retroactively eliminate the ...

Home January 22, 2024
Home
News | Cardiovascular Business

January 22, 2024 — A physician-scientist from Massachusetts researching whether chemicals naturally occurring in foods ...

Home January 22, 2024
Home
News | Cardiovascular Business

January 22, 2024 — Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently ...

Home January 22, 2024
Home
News | Cardiovascular Business

January 12, 2024 — The Heart Surgeon’s Cookbook is the brainchild of New York-based Cardiovascular and Thoracic Surgeon ...

Home January 12, 2024
Home
News | Cardiovascular Business

January 8, 2024 — GE HealthCare announced it has entered into an agreement to acquire MIM Software, a global provider of ...

Home January 08, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

As the Diagnostic and Interventional Cardiology (DAIC) team welcomes in the New Year, we also have taken a few moments ...

Home January 05, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Here is a rundown of what you and your colleagues found to be most interesting in the field of diagnostic and ...

Home January 02, 2024
Home
Subscribe Now